Abstract: The present disclosure generally relates to microfluidic devices, which may contain hydrogels in certain embodiments. In some aspects, a hydrogel or other scaffold medium may be present within a first microfluidic channel, and cells that are present may be imaged. The cells may be kept alive by exposure to cell media, which may be supplied via a second microfluidic channel. The first and second microfluidic channels may meet at a common interconnect region, in which the hydrogel can be directly exposed to the cell media, and nutrients, dissolved gases, waste, etc., can pass from the media to the cells or vice versa, e.g., through the hydrogel. In addition, in some cases, a polymer may be present between the hydrogel and the microfluidic channel, e.g., to position the hydrogel relative to one or more walls of the microfluidic channel. Other embodiments are generally directed to methods of making or using such devices, kits using such devices, or the like.

Abstract: The present disclosure generally relates to microfluidics, and to spatially controlling fluidic flows. In some embodiments, a fluid in a first microfluidic channel may be prevented from entering a second microfluidic channel due to a trench or other feature separating the channels. Using a trench may avoid the use of pillars, columns, bumps, or other barriers to separate the channels. Thus, for example, a fluid in a first microfluidic channel may be hardened to form a hydrogel, while the second microfluidic channel may remain free of the fluid and the hydrogel. This may allow a barrierless interface between the hydrogel and fluid within the second channel to be formed. Other embodiments are generally directed to devices containing such structures, methods or kits using such structures, or the like.

Abstract: An example manufacturing method includes performing first ion implantation into a first area of a substrate to form a buried layer. Second ion implantation into a second area of the substrate is performed to form a pre-dopant, where the second area is disposed around a periphery of the first area, and a thermal diffusion capability of ions in the pre-dopant is higher than a thermal diffusion capability of ions at the buried layer. An epitaxial layer is formed on a side, of the substrate, on which the buried layer and the pre-dopant are disposed. Third ion implantation into the epitaxial layer is performed, in correspondence to the second area, to form a deep well. Thermal annealing is performed to thermally diffuse ions at the buried layer, in the pre-dopant, and in the deep well.

Abstract: Described here is a composition comprising amphiphilic silica nanoparticles, wherein the silica nanoparticles are partially fluorinated. Also described here is a method for droplet-based assay, comprising dispersing at least one aqueous droplet in a continuous fluorous phase in a microfluidic channel, wherein at least one amphiphilic silica nanoparticle is absorbed to the interface of the continuous fluorous phase and the aqueous droplet, and wherein the silica nanoparticle is partially fluorinated. Further described here is a method for droplet-based assay, comprising dispersing at least one aqueous phase droplet in a continuous fluorous phase in a microfluidic channel, wherein the continuous fluorous phase comprises at least one partially fluorinated amphiphilic particle adsorbed to an interface of the continuous fluorous phase and the aqueous phase droplet, and wherein the aqueous phase droplet comprises at least one hydrophilic polymer adsorbed to the amphiphilic particle at the interface.

Abstract: Disclosed are salts of a compound of formula 1, as shown below, where R1, R2, R3, R4? R5, R6 and R7 are as described herein. Also, disclosed is a process for the preparation of the salts of the compounds of formula 1, and intermediates used therein. The salts of the compound of formula 1 can be useful for preparation of halichondrin analogs such as eribulin.

Abstract: A computerized hydrologic modeling system and method for performing accurate hydrologic determination using disparate weather data sources. Weather observation data are received for a geographical region, the weather observation data comprising data having a first temporal and spatial resolution for a first parameter set. Weather model data are received for the geographical region, the weather model data comprising data having a second temporal and spatial resolution for a second parameter set. Either the weather observation data or the weather model data or both are processed to provide a common scale dataset having a common temporal and spatial resolution for the parameters of the first and second parameter sets. A historical dataset is retrieved comprising historical observation data for the first and second parameter sets. The common scale dataset is bias-corrected to be statistically consistent with the historical observation data.

Abstract: A method and an apparatus for data transfer between network devices are suggested. It is proposed to introduce a network file transfer protocol into the data transfer between a NMS and a NE in order to improve the communication efficiency there between. Generally, when a NMS is to retrieve data from a NE, it will send a message to the NE to prepare a data file which can support a network file transfer protocol. Then the data file will be transmitted from the NE to the NMS by the network file transfer protocol.

Abstract: In some cases, an IPTV client may send multiple IGMP Report/Join requests to an IPTV gateway, primarily due to a system or software failure. This may flood the IPTV client device with unwanted streaming data. A method and an apparatus for managing Internet Group Management Protocol (IGMP) multicast groups of IPTV service are suggested. The method comprises receiving a request from an IPTV client device for joining a new IGMP multicast group of IPTV service; and adjusting IGMP multicast groups of the IPTV client device according to a preset rule as a function of the number of the IGMP multicast groups which are joined by the IPTV client device over a preset value. According to the disclosure, only a preset number of IGMP groups are allowed for an IPTV client device, which can reduce the risk of streaming data flooding the system.

Abstract: A method and an apparatus for communication between a first network device and second network device are suggested. The method comprises, at the level of the first network device: receiving, from the second network device, one or more requests for SNMP Set operation; caching the one or more requests; and upon a determined time period being reached, processing the cached one or more requests. A cache mechanism is suggested so that an SNMP agent can cache the requests for SNMP Set operation for a time period and process these requests in batch.

Abstract: Disclosed is a compound of formula 1, or a pharmaceutically acceptable salt thereof, where R1, R2, R3, R4, R5, R6, R7, R7?, R8, R9, R10, R11, R12 and R13 are as disclosed herein. Also, disclosed is a process for the preparation of the compound of formula 1, or a pharmaceutically acceptable salt thereof, and intermediates used therein. The compound of formula 1 can be used in the preparation of halichondrin analogs, such as Eribulin; and a process for its preparation from the compound of formula 1 is also disclosed.

Abstract: Disclosed is a compound of formula 1, or a pharmaceutically acceptable salt thereof, where R1, R2, R3, R4, R5, R6, R7, R7?, R8, R9, R10, R11, R12 and R13 are as disclosed herein. Also, disclosed is a process for the preparation of the compound of formula 1, or a pharmaceutically acceptable salt thereof, and intermediates used therein. The compound of formula 1 can be used in the preparation of halichondrin analogs, such as Eribulin; and a process for its preparation from the compound of formula 1 is also disclosed.

Abstract: Disclosed are salts of a compound of formula 1, as shown below, where R1, R2, R3, R4? R5, R6 and R7 are as described herein. Also, disclosed is a process for the preparation of the salts of the compounds of formula 1, and intermediates used therein. The salts of the compound of formula 1 can be useful for preparation of halichondrin analogs such as eribulin.

Abstract: Disclosed is a compound of formula 1, or a pharmaceutically acceptable salt thereof, where R1, R2, R3, R4, R5, R6, R7, R7?, R8, R9, R10 , R11 , R12 and R13 are as disclosed herein. Also, disclosed is a process for the preparation of the compound of formula 1, or a pharmaceutically acceptable salt thereof, and intermediates used therein. The compound of formula 1 can be used in the preparation of halichondrin analogs, such as Eribulin; and a process for its preparation from the compound of formula 1 is also disclosed.

Abstract: Disclosed is a compound of formula 1, or a pharmaceutically acceptable salt thereof, where R1, R2, R3, R4, R5, R6, R7, R7?, R8, R9, R10, R11, R12 and R13 are as disclosed herein. Also, disclosed is a process for the preparation of the compound of formula 1, or a pharmaceutically acceptable salt thereof, and intermediates used therein. The compound of formula 1 can be used in the preparation of halichondrin analogs, such as Eribulin; and a process for its preparation from the compound of formula 1 is also disclosed.

Abstract: Described here is a composition comprising amphiphilic silica nanoparticles, wherein the silica nanoparticles are partially fluorinated. Also described here is a method for droplet-based assay, comprising dispersing at least one aqueous droplet in a continuous fluorous phase in a microfluidic channel, wherein at least one amphiphilic silica nanoparticle is absorbed to the interface of the continuous fluorous phase and the aqueous droplet, and wherein the silica nanoparticle is partially fluorinated. Further described here is a method for droplet-based assay, comprising dispersing at least one aqueous phase droplet in a continuous fluorous phase in a microfluidic channel, wherein the continuous fluorous phase comprises at least one partially fluorinated amphiphilic particle adsorbed to an interface of the continuous fluorous phase and the aqueous phase droplet, and wherein the aqueous phase droplet comprises at least one hydrophilic polymer adsorbed to the amphiphilic particle at the interface.

Abstract: Disclosed is a compound of formula 1, or a pharmaceutically acceptable salt thereof, where R1, R2, R3, R4, R5, R6, R7, R7?, R8, R9, R10, R11, R12 and R13 are as disclosed herein. Also, disclosed is a process for the preparation of the compound of formula 1, or a pharmaceutically acceptable salt thereof, and intermediates used therein. The compound of formula 1 can be used in the preparation of halichondrin analogs, such as Eribulin; and a process for its preparation from the compound of formula 1 is also disclosed.

Abstract: The specification relates to compounds and process for the preparation of a compound of formula 7, where LG is a leaving group and hal is a halide and is Cl, Br or I. The compound of formula 7 can be useful in the preparation of natural products, such as halichondrin and its derivatives.

Abstract: Disclosed is a compound of formula 1, as shown below, where R1, R2, R3, R4, R5, R6 and R7 are as described herein. Also, disclosed is a process for the preparation of compounds of formula 1, and intermediates used therein. The compound of formula 1 can be useful for preparation of halichondrin analogs such as Eribulin.

Abstract: Disclosed is a compound of formula 1, or a pharmaceutically acceptable salt thereof, where R1, R2, R3, R4, R5, R6, R7, R7?, R8, R9, R10, R11, R12 and R13 are as disclosed herein. Also, disclosed is a process for the preparation of the compound of formula 1, or a pharmaceutically acceptable salt thereof, and intermediates used therein. The compound of formula 1 can be used in the preparation of halichondrin analogs, such as Eribulin; and a process for its preparation from the compound of formula 1 is also disclosed.

Abstract: Disclosed is a compound of formula 1, as shown below, where R1, R2, R3, R4, R5, R6 and R7 are as described herein. Also, disclosed is a process for the preparation of compounds of formula 1, and intermediates used therein. The compound of formula 1 can be useful for preparation of halichondrin analogs such as Eribulin.